You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

Alvogen Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for ALVOGEN

ALVOGEN has fifty-seven approved drugs.

There are two tentative approvals on ALVOGEN drugs.

Drugs and US Patents for Alvogen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alvogen BUTALBITAL, ACETAMINOPHEN AND CAFFEINE acetaminophen; butalbital; caffeine TABLET;ORAL 204984-001 Jan 10, 2017 DISCN No No ⤷  Try for Free ⤷  Try for Free
Alvogen NEVIRAPINE nevirapine TABLET, EXTENDED RELEASE;ORAL 204621-002 Nov 9, 2015 DISCN No No ⤷  Try for Free ⤷  Try for Free
Alvogen OXYCODONE AND ACETAMINOPHEN acetaminophen; oxycodone hydrochloride TABLET;ORAL 202677-003 Mar 8, 2016 AA RX No No ⤷  Try for Free ⤷  Try for Free
Alvogen BUPRENORPHINE buprenorphine FILM, EXTENDED RELEASE;TRANSDERMAL 207490-001 May 17, 2022 AB RX No No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Alvogen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alvogen SPECTAZOLE econazole nitrate CREAM;TOPICAL 018751-001 Dec 23, 1982 3,839,574 ⤷  Try for Free
Alvogen TRANDATE labetalol hydrochloride TABLET;ORAL 018716-004 Aug 1, 1984 4,012,444 ⤷  Try for Free
Alvogen TAMBOCOR flecainide acetate TABLET;ORAL 018830-002 Oct 31, 1985 4,642,384 ⤷  Try for Free
Alvogen TAMBOCOR flecainide acetate TABLET;ORAL 018830-001 Oct 31, 1985 4,005,209 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Alvogen – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Alvogen has emerged as a significant player, carving out a unique position for itself through strategic growth and targeted acquisitions. Let's dive into an in-depth analysis of Alvogen's market position, strengths, and strategic insights that have propelled this company to the forefront of the pharmaceutical landscape.

The Rise of Alvogen

Alvogen's journey began in 2009 when Robert Wessman, the company's founder, sketched out a business plan on a restaurant napkin[1]. From these humble beginnings, Alvogen has grown into a formidable force in the pharmaceutical industry, with a commercial presence in 35 countries and a global turnover of almost $800 million as of 2015[2].

A Vision for Growth

Alvogen's rapid ascent in the pharmaceutical industry is underpinned by a clear vision:

"Our vision is to become the preferred partner by setting a new standard for the future of pharma."[9]

This vision has driven Alvogen to pursue a targeted growth strategy, focusing on high-quality, difficult-to-make pharmaceutical products. By 2025, Alvogen aims to be a leading generic pharmaceutical company and a preferred partner that continuously provides meaningful differences in the lives of the people they serve[9].

Alvogen's Market Position

Alvogen has strategically positioned itself as a key player in the generic pharmaceutical market, with a particular focus on complex, high-value products. Let's examine the factors contributing to Alvogen's strong market position.

Global Presence

Alvogen's market reach extends across 35 countries, demonstrating its global ambitions and capabilities[2]. This extensive geographical footprint allows the company to tap into diverse markets and leverage regional opportunities.

Diverse Portfolio

Alvogen's product portfolio spans various therapeutic areas, including:

  • Complex inhalation products
  • Injectables
  • Strategic 505(b)(2) products
  • Generic medications
  • Branded pharmaceuticals[1][5]

This diverse range of offerings enables Alvogen to cater to different market segments and maintain a competitive edge.

Strong R&D Capabilities

With over 50 products currently on the market and extensive R&D capabilities fueling its growing pipeline, Alvogen demonstrates a commitment to innovation and continuous product development[1][5].

Alvogen's Key Strengths

Alvogen's success in the pharmaceutical industry can be attributed to several key strengths that set it apart from competitors.

1. Strategic Acquisitions

Alvogen has pursued a growth strategy that combines organic expansion with strategic acquisitions. Notable acquisitions include:

  • Labormed in Romania
  • Kunwha and Dream Pharma in South Korea
  • Lotus in Taiwan[2]

These acquisitions have allowed Alvogen to expand its geographical reach and enhance its product portfolio rapidly.

2. Focus on Complex Generics

Alvogen has strategically focused on developing complex, high-value generic products. This approach allows the company to target niche markets with less competition and higher profit margins[1].

3. Strong Leadership

Under the guidance of Robert Wessman, who served as CEO until 2022 and continues as chairman, Alvogen has benefited from experienced leadership with a clear vision for growth[1].

4. Efficient Operations

Alvogen prides itself on being a lean organization with a continuous focus on operational efficiency and cost optimization[9]. This approach allows the company to remain competitive in the challenging generic pharmaceutical market.

5. Quality Commitment

Alvogen is committed to maintaining the highest quality standards for all its products and services[9]. This commitment has earned the company several service awards, including the HDMA Diana Award and McKesson Trade Partner of the Year Awards[2].

Strategic Insights: The Alvogen STARMAP

Alvogen's strategic roadmap, known as the STARMAP, outlines the company's customer commitments and provides insights into its future direction[9].

Portfolio Strategy

Alvogen focuses on building a well-targeted and profitable portfolio in all its markets to serve customers effectively. This strategy involves:

  • Developing complex, high-value generics
  • Expanding into biosimilars through sister company Alvotech
  • Pursuing first-to-market and first-to-file opportunities[2]

Quality Assurance

Maintaining the highest quality standards is a cornerstone of Alvogen's strategy. This commitment to quality extends across all products and services, enhancing customer trust and brand reputation[9].

Service Excellence

Alvogen continuously focuses on providing consistent and reliable high-quality service to its customers. This commitment has resulted in several industry awards and recognitions[2][9].

Talent Management

Recognizing the importance of human capital, Alvogen focuses on selecting and retaining the best talent in every field. This approach fuels the company's success through a performance-driven culture[9].

Cost Optimization

As a lean organization, Alvogen maintains a continuous focus on operational efficiency and cost optimization. This strategy allows the company to remain competitive in the challenging generic pharmaceutical market[9].

Future Growth Prospects

Alvogen's future growth prospects appear promising, driven by several factors:

1. Expansion into Biosimilars

Through its sister company Alvotech, Alvogen is positioning itself to capitalize on the growing biosimilars market. With a pipeline covering major biologics coming off-patent in the next 10 years, Alvogen is set to launch biosimilar products from 2019 onwards[2].

2. Geographic Expansion

Alvogen has identified several markets for potential strategic investments, including Latin America, Thailand, Russia, the Philippines, and Indonesia[2]. This geographic expansion strategy could open up new growth opportunities for the company.

3. First-to-Market Opportunities

Almost half of Alvogen's US pipeline of around 60 ANDAs pending approval are potential first-to-market or first-to-file opportunities[2]. These opportunities could provide Alvogen with significant competitive advantages in the generic pharmaceutical market.

4. Strategic Partnerships

Alvogen values partnerships and collaboration, with its future strategy relying heavily on strategic selection of partners worldwide[1]. This approach could lead to synergies and accelerated growth in various markets.

Challenges and Competition

Despite its strong position, Alvogen faces several challenges in the competitive pharmaceutical landscape:

Industry Consolidation

The generic pharmaceutical industry is experiencing ongoing consolidation, both in retail and wholesale sectors. This trend could potentially squeeze smaller players like Alvogen[2].

Patent Expirations

With fewer small molecules coming off patent, generic pharmaceutical companies need to diversify their portfolios to maintain growth. Alvogen's focus on complex generics and biosimilars is a strategic response to this challenge[2].

Regulatory Hurdles

As a global player, Alvogen must navigate complex regulatory environments across different markets. The company's regulatory expertise will be crucial in overcoming these hurdles[2].

Competition from Established Players

Alvogen competes with both local and global pharmaceutical companies. In Iceland, for instance, it faces competition from established players like Johnson & Johnson, Novartis AG, Pfizer Inc, and Sanofi SA[4].

Key Takeaways

  1. Alvogen has rapidly grown from a startup in 2009 to a global pharmaceutical company with a presence in 35 countries.

  2. The company's focus on complex, high-value generics and strategic acquisitions has driven its growth and market positioning.

  3. Alvogen's STARMAP strategy emphasizes portfolio development, quality assurance, service excellence, talent management, and cost optimization.

  4. Future growth prospects include expansion into biosimilars, geographic expansion, and capitalizing on first-to-market opportunities.

  5. Despite facing challenges such as industry consolidation and regulatory hurdles, Alvogen's strategic approach positions it well for future success in the pharmaceutical industry.

FAQs

  1. What is Alvogen's primary focus in the pharmaceutical industry? Alvogen primarily focuses on developing, manufacturing, and marketing complex, high-value generic pharmaceutical products.

  2. How has Alvogen achieved its rapid growth since 2009? Alvogen's growth has been driven by a combination of organic expansion, strategic acquisitions, and a focus on developing complex generic products.

  3. What is the Alvogen STARMAP? The Alvogen STARMAP is the company's strategic roadmap that outlines its customer commitments, focusing on portfolio strategy, quality assurance, service excellence, talent management, and cost optimization.

  4. How is Alvogen positioning itself for future growth? Alvogen is expanding into biosimilars through its sister company Alvotech, pursuing geographic expansion, and focusing on first-to-market opportunities in the generic pharmaceutical market.

  5. What are the main challenges Alvogen faces in the pharmaceutical industry? Key challenges include industry consolidation, fewer small molecules coming off patent, regulatory hurdles in different markets, and competition from established pharmaceutical companies.

Sources cited: [1] https://www.alvogen.com [2] https://www.alvogen.com/newsroom/alvogens-strategy-is-delivering-global-growth [4] https://www.mordorintelligence.com/industry-reports/iceland-pharmaceutical-market/companies [5] https://www.alvogen.com/company [9] https://www.alvogen.com/company/our-vision

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.